Innovation Pharmaceuticals Inc (IPIX)

[georgejjl]

ANSWER THIS QUERY

IF

"...Among patients with the severest form of psoriasis, those having a baseline IGA score of 3 (“moderate”), the primary endpoint was met in 46% of patients who received 200mg per day."

THEN what percentage of patients with the severest from of psoriasis, with a base line score of 3 or higher will meet the primary endpoint at 400 mg/day double the daily 200 mg/day maximum dose of this past trial???

[color=red]In the second half of 2016, Cellceutix plans to initiate a Phase 2b trial of Prurisol, testing higher dosing regimens (300mg and 400mg arms),for the treatment of moderate-to-severe psoriasis.[/color The company also is exploring Prurisol’s use in treating eczema.]

Good luck and GOD bless,

George